There was a phase-2 trial in Behçet’s uveitis.Found it: http://investors.xoma.com/releasedetail.cfm?ReleaseID=528942 . Any comments on the market size here? Wonder what projections are in this indication and can't recall off-hand the economics of the Servier deal.